Call Options

6 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1.9 - $2.4 $5,890 - $7,440
3,100 Added 110.71%
5,900 $12,000
Q2 2024

Aug 14, 2024

BUY
$1.86 - $3.35 $5,208 - $9,380
2,800 New
2,800 $5,000
Q4 2023

Feb 14, 2024

SELL
$0.97 - $3.55 $2,425 - $8,875
-2,500 Reduced 83.33%
500 $1,000
Q3 2023

Nov 14, 2023

SELL
$1.58 - $2.86 $3,634 - $6,578
-2,300 Reduced 43.4%
3,000 $4,000
Q2 2023

Aug 14, 2023

BUY
$1.72 - $2.12 $9,116 - $11,236
5,300 New
5,300 $10,000
Q4 2022

Feb 14, 2023

BUY
$1.85 - $2.6 $1,295 - $1,820
700 New
700 $1,000

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $85.1M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.